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Abstract Lung cancer is the leading cause of cancer-
related mortality in the world, resulting in over a million
deaths each year. Non-small cell lung cancers (NSCLCs)
are characterized by a poor immunogenic response, which
may be the result of immunosuppressive factors such as
prostaglandin E2 (PGE2) present in the tumor environment.
The eVect of PGE2 in the suppression of anti-tumor immunity
and its promotion of tumor survival has been established
for over three decades, but with limited mechanistic under-
standing. We have previously reported that PGE2 activates
hematopoietic progenitor kinase 1 (HPK1), a hematopoietic-
speciWc kinase known to negatively regulate T-cell receptor
signaling. Here, we report that mice genetically lacking
HPK1 resist the growth of PGE2-producing Lewis lung car-
cinoma (LLC). The presence of tumor-inWltrating lympho-
cytes (TILs) and T-cell transfer into T cell-deWcient mice
revealed that tumor rejection is T cell mediated. Further
analysis demonstrated that this may be signiWcantly due to
the ability of HPK1¡/¡ T cells to withstand PGE2-mediated
suppression of T-cell proliferation, IL-2 production, and
apoptosis. We conclude that PGE2 utilizes HPK1 to sup-
press T cell-mediated anti-tumor responses.
Keywords T cell · Tumor immunology · 
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Introduction
Tumor escape, the last phase of the cancer immunoediting
model, is characterized by the emergence of somatic
mutants that have acquired suYcient gain/loss of function
defects, which allows these cancer cells to resist eradication
by the immune system [9]. Of these evasive mechanisms,
production of immunosuppressive factors by tumor cells is
recognized as one of the most eVective means to disarm
anti-tumor immunity.
One of the characteristic aberrations found in cancers,
such as non-small lung cancers (NSLCs), is the upregulation
of cyclooxygenase 2 (COX-2) [13, 15, 43], the rate-limiting
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enzyme that catalyzes the conversion of arachidonic acid
into Wve classes of prostanoids, of which prostaglandin
E2 (PGE2) is the predominant by-product [6]. PGE2 is a
multifunctional ligand whose biological actions are deter-
mined in part by the type of E prostanoid receptors (EP) it
binds [26, 27]. In many transformed cells, PGE2 engage-
ment initiates signals that block apoptosis, promote angio-
genesis and stimulate tumor growth [12, 15, 16, 20, 24, 42].
Paradoxically, the binding of tumor-derived PGE2 to EP
receptors expressed on T cells initiates a cascade of immun-
oinhibitory signals that block T-cell proliferation, IL-2 pro-
duction and tumor necrosis factor (TNF) secretion [8, 10,
28, 31, 35]. In addition, PGE2 can inhibit T-cell functions
indirectly by inducing the synthesis of immunosuppressive
cytokines such as IL-10 [40]. Therefore, the ability of PGE2
to promote tumor growth while suppressing the functions
of immune cells makes it an ideal mechanism for cancer
cells to utilize for their growth and survival.
The pro-growth properties of PGE2 on epithelial cells
and its anti-proliferative eVects on hematopoietic cells led
us to hypothesize that a hematopoietic cell-restricted negative
regulator may contribute to the PGE2-mediated immune
suppression. Our discovery that PGE2 stimulation activated
hematopoietic progenitor kinase 1 (HPK1) [34] led us to
investigate whether this hematopoietic cell-restricted member
of the Ste20 family of serine/threonine kinases plays a role
in the PGE2-mediated suppression of the anti-tumor immune
response. HPK1 was considered as a candidate because it is
also a known negative regulator of T-cell receptor signaling
pathways [17, 19, 38]. In this report, we assess the impact
of the loss of HPK1 on PGE2-mediated functions. We use a
genetic approach to study the role of HPK1 in mounting an
eVective immune response against a PGE2-secreting murine
tumor, the Lewis lung carcinoma (LLC).
Materials and methods
Animals
HPK1¡/¡ mice were generated as follows: a 4.7 kb geno-
mic BamHI–XhoI fragment covering the Wrst three exons of
HPK1 was inserted into a pMC1-neo vector, which served
as the long arm of the targeting construct. The second half
of exon 1 and the adjacent intron were replaced with a
PGK1-neo selection cassette in antisense orientation. A
466 bp fragment starting with exon 2 was generated by
PCR ampliWcation and served as the short arm of the target-
ing construct. The linearized construct was electroporated
into E14 embryonic stem cells. Positive clones were identi-
Wed by PCR with the primers: 5-GGG AGC CAA GAA
ATT TGA GAG CTC-3 (common primer), 5-CCG GTG
GAT GTG GAA TGT GTG-3 (targeted allele) and CCC
TTC TGT CTC CTC CAC CAC (wild-type allele), and
injected into C57BL/6 blastocysts. Mice lacking RAG2 on a
C57BL/6 background and wild-type controls were from
Taconic (Hudson, NY).
Antibodies, media and reagents
The following antibodies were used for T-cell stimulation
and FACS staining of intracellular and cell surface markers.
All were from Becton-Dickinson (BD) Pharmingen (San
Jose, CA): anti-murine CD3, CD28, CD4-FITC, IL-2-PE,
and unlabeled and biotinylated anti-murine IL-2. Annexin
V-PE, 7-AAD (7-Amino-Actinomycin D), and GolgiStop
were also from BD Pharmingen. Anti CD3,CD4, and CD8
mAbs used for immunohistological studies were purchased
from Ventana Medical Systems (Tucson, AZ). Polyclonal
rabbit anti-EP receptor antibodies were purchased from
Cayman Chemicals (Ann Arbor, MI). Polyclonal rabbit
anti--actin was purchased from Rockland Immunochemi-
cals (Gilbertsville, PA). RPMI 1640 media (Cellgro, Hern-
don, VA), supplemented with 10% bovine calf serum
(Gemini Bio-products, West Sacramento, CA), -mercap-
toethanol (50 M) from Gibco (Carlsbad, CA), and L-gluta-
mine (2 mM)/penicillin (100 U/mL)/streptomycin (100 g/
mL) also from Gemini Bio-Products were used as compo-
nents for complete medium. Quillaja Bark Saponin was
from Sigma-Aldrich (St. Louis, MO). Prostaglandin E2 was
from Calbiochem (San Diego, CA).
Proliferation assay
Negatively selected, puriWed T cells were prepared using
the Pan T-cell isolation kit from Miltenyi Biotech, Inc.
(Auburn, CA). 2 £ 105 T cells were seeded in a 96-well
plate and incubated with various dilutions of anti-CD3 and
0.5 g/mL of anti-CD28 for 72 h in the presence or absence
of 1 nM PGE2. Cells were pulsed with 1 Ci/well 3H-thy-
midine (MP Biomedicals, Irvine, CA) for 18 h before harvest.
Enzyme-linked immunosorbent assay (ELISA)
Supernatants from the proliferation assay were collected for
ELISA prior to addition of 3H-thymidine. Supernatants from
CTL assay were collected after 18 h of culture in an E:T ratio
of 40:1. Protocol used for ELISA followed BD Pharmingen
instructions (for IL-2) and R&D instructions (for IFN-).
Intracellular staining, apoptosis, and FACS analysis
RBC-lysed wild-type or HPK1¡/¡ splenocytes were stimu-
lated with or without 1 nM PGE2 and 1 g/mL anti-CD3
plus 0.5 g/mL anti-CD28 for 72 h in the presence of
GolgiStop for the last 5 h of culture. Cells were then WxedCancer Immunol Immunother (2010) 59:419–429 421
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with 2% paraformaldehyde, followed by permeabilization
with a buVer containing 0.1% saponin and 0.1% BSA. Cells
were then incubated with PE-conjugated anti-IL-2 mAb for
30 min. IL-2 producing cells were determined by Xow
cytometry using FACSCalibur and analyzed using FlowJo
software (FlowJo, LLC, Ashland, OR). For measurement of
apoptosis, HPK1¡/¡ and wild-type T cells were stimulated
as above, with or without PGE2 and then stained with
annexin V-PE and 7AAD after 72 h of culture.
LLC tumor model
Lewis lung carcinoma tumor cell line (clone 3LL) was
obtained from ATCC (Manassas, VA). 3LL cells (5 £ 105)
were injected intravenously into the retro-orbital sinus.
Mice were killed 14 days post-cell injection using carbon
dioxide asphyxiation, and lung tissue was collected and
Wxed in 10% buVered formalin for histological analysis. In
mice that received drug treatment, 2.5 mg/kg of COX-2
inhibitor II (SC-791) from Calbiochem (San Diego, CA) in
PBS was administered to mice intraperitonially three times
per week for the duration of the study. Tumor burden was
quantiWed by both the number of foci in total lung tissue
and the total tumor area in the lungs; assessed by micro-
scopic examination with a calibrated grid using Sigma Scan
software (Systat Software, San Jose, CA).
Histology
Lung tissue was stained with hematoxylin and eosin
(H&E), as well as anti-CD3, CD4, and CD8 antibodies
for immunohistochemistry analysis. Tumor burden was
assessed by microscopic examination of H&E stained sec-
tions that show visible foci.
Immunohistochemistry
Anti CD3, CD4, and CD8 antibodies require antigen retrieval
in 0.01 M citrate of pH 6.0 for 10, 20, and 20 min, respec-
tively. The primary antibodies were detected using biotinyla-
ted goat anti-mouse secondary antibody followed by
streptavidin–biotin peroxidase conjugate. The complex con-
taining peroxidase was visualized by the addition of diam-
inobenzidine (DAB). Tissue sections were counter-stained
with hematoxylin and samples were mounted using “per-
mount”, a permanent mounting media (Fisher ScientiWc, Pitts-
burgh, PA). All other reagents were from Ventana Nexus and
the detection was carried out on a Ventana Nexus instrument.
CTL and IFN- assay
3LL cells were irradiated and labeled with 200 Ci/mL
51Cr. Splenocytes from tumor-bearing animals were
depleted of red blood cells by treating them with RBC lysis
buVer (Sigma-Aldrich). Cytotoxicity against 3LL was mea-
sured at variable eVector to target (E:T) ratios after 6 h of
co-culture in V-bottom 96-well plates, in the presence of
10 U/mL of IL-2. Percent lysis was calculated using the fol-
lowing formula: (%cytotoxicity = 100 £ E ¡ min/max ¡ min)
where “min” is the minimum (target cells alone) and “max”
is maximum (100%) lysis. For IFN- analysis, RBC-lysed
splenocytes from 3LL-injected mice were stimulated ex
vivo at a 40:1 ratio of T cells to irradiated 3LL cells for
18 h, and IFN- levels were determined by ELISA
according to the manufacturer’s instructions. All reagents for
IFN- ELISA were from R&D Systems, Inc. (Minneapolis,
MN).
T-cell transfer
Cells were puriWed from the spleen and lymph nodes of
HPK1¡/¡ and wild-type littermates by negative selection as
described above. In all experiments, T-cell purity was
between 94 and 98% as assessed by anti CD3-FITC stain-
ing. PuriWed T cells (20 £ 106) were injected intravenously
into the retro-orbital sinus of RAG2¡/¡ mice at the same
time as the intravenous injection of 3LL (as above).
Statistical analysis
Error bars represent the standard error of the mean, as indi-
cated in the Wgure legends. DiVerences were analyzed
using Student’s t test. P values of <0.05 were regarded as
signiWcant.
Results
Generation of HPK1 knockout mice
We have previously demonstrated that PGE2 activates
hematopoietic progenitor kinase 1 (HPK1) [34], a known
negative regulator of T-cell receptor signaling [19, 32, 38].
We, therefore, investigated whether HPK1 may be respon-
sible for the PGE2-induced suppression of T cell-mediated
responses. To address this, we generated mice lacking
HPK1 using standard homologous recombination techniques
(Fig. 1a–d). HPK1¡/¡ mice were healthy, reproduced with
Mendelian ratios and had a normal life span (data not
shown). Analysis revealed that CD4+ to CD8+ T-cell
ratios in the thymus, lymph nodes, and spleen were nor-
mal in HPK1¡/¡ mice when compared to T cells from
wild-type animals (Fig. 1e). These results suggested that the
lack of HPK1 does not aVect T-cell development, in agreement
with a recent report from Tan et al. who independently
generated an HPK1-deWcient mouse [38].422 Cancer Immunol Immunother (2010) 59:419–429
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Fig. 1 Generation of HPK1-deWcient mice. a Gene-targeting strategy.
Top a portion of the wild-type murine HPK1 locus showing relevant
restriction sites: BamHI, EcoRI, XhoI, and XbaI. Exons are shown as
Wlled rectangles and the position of the 3 Xanking probe is indicated.
The structure of the targeting vector (middle) and the mutant locus
(bottom) are also shown. b PCR-based genomic analysis for HPK1¡/¡
mice. Tail genomic DNA was subjected to PCR analysis using primer
pairs speciWc for the wild-type HPK1 allele and neo-speciWc primer.
A 726-nucleotide fragment is expected for the wild-type allele and a
670-nucleotide fragment for the HPK1-disrupted allele. c Southern
blot analysis of tail DNA isolated from wild-type, heterozygous
(HPK1+/¡), and HPK1¡/¡ mice. Genomic DNA was digested with
EcoRI and hybridized with the 3 Xanking probe. A 2.4-kb fragment is
expected for the wild-type allele and a 3.8-kb fragment would indicate
the presence of the neomycin cassette. d Western blot analysis of pro-
tein lysates from spleens of wild-type and knockout mice using anti-
bodies against HPK1. e CD4+ and CD8+ ratios in the thymus (thy),
lymph nodes (ln) and spleen (sp) of wild-type and HPK1¡/¡ miceCancer Immunol Immunother (2010) 59:419–429 423
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HPK1¡/¡ T cells are resistant to PGE2-mediated 
suppression of IL-2 production
The best-characterized eVects that PGE2 exerts on T cells
are its negative impact on TCR-induced IL-2 production
and proliferation [8,  22,  28]. Therefore, we investigated
whether the absence of HPK1, a known negative regulator
of TCR-induced IL-2 production [19], would alter the abil-
ity of PGE2 to inhibit IL-2 production. T cells from the
spleens of HPK1¡/¡ or wild-type mice were co-stimulated
with plate-bound anti-CD3 and soluble anti-CD28 mAbs
(CD3 + CD28) for 72 h, in the presence or absence of
PGE2. The amount of IL-2 in the supernatants of these
stimulated T cells was determined by ELISA (Fig. 2a, left
panel). HPK1¡/¡ T cells exposed to PGE2 were markedly
resistant to the inhibitory eVect of PGE2 on IL-2 production
when compared to identically treated wild-type T cells.
SpeciWcally, HPK1¡/¡ T cells stimulated with PGE2 pro-
duced 26% less IL-2 than those left untreated, whereas an
88% reduction was observed in identically stimulated wild-
type T cells (Fig. 2a, left panel). Anti-IL-2 intracellular
staining conWrmed that HPK1¡/¡ T cells were more resis-
tant to PGE2-mediated inhibition of IL-2 production
(Fig. 2a, right panel), as indicated by the 9% reduction of
IL-2+ CD4+ HPK1¡/¡ T cells, compared to a 75% reduction
of IL-2+ CD4+ T cells from wild-type mice. Because the
resistance to PGE2-mediated suppression could have been
caused by the diminished expression of the prostaglandin
E2 receptors (EP1–EP4) in HPK1¡/¡ T cells, we performed
Western blot analyses on lymphocyte whole cell lysates
prepared from wild-type and HPK1¡/¡ lymph nodes, using
antibodies that recognize speciWc EP receptors. Analysis of
the EP Western blot data revealed that the absence of HPK1
did not reduce the expression of the EP receptors, when the
EP expression levels were compared to the amounts of pro-
teins in the loading control lanes (see Supplemental Fig. 1).
These  Wndings support the conclusion that the lack of
HPK1 renders T cells signiWcantly resistant to PGE2-medi-
ated inhibition of IL-2 production.
HPK1¡/¡ T cells are resistant to PGE2-mediated 
suppression of proliferation
Given that PGE2 stimulation also inhibits TCR-induced
T-cell proliferation [22], we investigated whether the loss of
HPK1 would have an impact on the anti-proliferative eVect
Fig. 2 Resistance of HPK1¡/¡ T cells to PGE2 inhibition of IL-2 pro-
duction and proliferation. T cells stimulated with 1 g/mL anti-CD3
and 0.5 g/mL anti-CD28 in the presence or absence of 1 nM PGE2.
a IL-2 levels of supernatants measured by ELISA (left panel) or intra-
cellular staining (right panel). b T-cell proliferation by 3H thymidine
incorporation. 3H thymidine was added in the last 18 h of stimulation.
c Line graphs representing proliferation (left panel) or IL-2 levels
(right panel) at varying anti-CD3 concentrations, as shown on the
X-axis. Cells were stimulated in 96-well plates for 3 days with the
varying anti-CD3 concentrations, and a Wxed amount of CD28
(0.5 g/mL) in the presence or absence of 1nM PGE2. As shown, Wlled
squares are HPK1¡/¡ and Wlled circles are wild-type T cells. Solid
symbols indicate conditions without PGE2 and open symbols are with
PGE2. d The degree of inhibition of proliferation on the addition of
PGE2 was compared when HPK1¡/¡ or wild-type T cells produced
comparable levels of IL-2 at 0.25 or 2 g/mL of anti-CD3 used for
stimulation, respectively. Error bars represent the standard error of the
mean of an experiment done in triplicate (*P <0 . 0 5 )424 Cancer Immunol Immunother (2010) 59:419–429
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induced by PGE2. We compared the levels of 3H-thymidine
incorporation by wild-type and HPK1¡/¡ T cells that were
stimulated with CD3 + CD28 for 72 h and found that prolif-
eration of HPK1¡/¡ T cells was only inhibited by 24% in the
presence of PGE2 (Fig. 2b). This degree of inhibition of
HPK1¡/¡ T cells by PGE2 was in contrast to the 77% reduc-
tion in the proliferation of wild-type T cells treated with
PGE2. Since we observed an increase in the levels of prolif-
eration and IL-2 production from HPK1¡/¡ when compared
to wild-type conditions in the absence of PGE2, the amount
of anti-CD3 used for stimulation was titrated to address
whether the resistance to PGE2-mediated inhibition may be
dispensable at a lower threshold levels of stimulation. At all
degrees of IL-2 production (Fig. 2c, right panel) and prolifer-
ation (Fig. 2c left panel) examined, there remained a signiW-
cant resistance to the addition of PGE2 in the absence of
HPK1 (Fig. 2c). Furthermore, we recognized that the amount
of IL-2 produced might aVect the degree of proliferation.
Therefore, we compared two points at which HPK1¡/¡ and
wild-type T cells produced similar amounts of IL-2, but at
diVerent anti-CD3 concentrations. The proliferation of
HPK1¡/¡ T cells at 0.25 g/mL of anti-CD3 used for stimu-
lation was inhibited by 28% when compared to the 88% inhi-
bition observed by wild-type T cells that produced similar
amounts of IL-2 at 2 g/mL of anti-CD3 (Fig. 2d). Taken
together, our results conWrm that the absence of HPK1 con-
fers T cells with a signiWcant resistance to PGE2-mediated
inhibition of both proliferation and IL-2 production.
HPK1¡/¡ T cells are resistant to PGE2-mediated induction 
of apoptosis
In addition to suppressing T-cell functions, PGE2 stimula-
tion has been shown to promote apoptosis in thymocytes
and mature peripheral T cells [25, 29, 41]. Since HPK1 is
known to act as a pro-apoptotic molecule in T cells [36], it
is possible that HPK1¡/¡ T cells are less susceptible to
apoptosis-inducing stimuli, such as PGE2. Indeed, in the
absence of HPK1, T cells stimulated by CD3 + CD28 for
72 h underwent less apoptosis as evidenced by Annexin V
staining when compared to identically treated wild-type T
cells (Fig. 3). Not only are HPK1¡/¡ T cells resistant to
TCR-induced apoptosis, but they are also resistant to apop-
tosis triggered by PGE2.
Prevention of Lewis lung carcinoma development 
by the ablation of HPK1
The ability of HPK1¡/¡ T cells to resist the immunosup-
pressive and pro-apoptotic action of PGE2 suggests that
Fig. 3 Resistance to apoptosis 
by HPK1¡/¡ T cells. HPK1¡/¡ 
or wild-type T cells, in the 
absence or presence of PGE2, 
were stained with 7AAD and 
Annexin V. The 7AAD negative 
population, which represents 
living cells, was assessed 
for Annexin V stainingCancer Immunol Immunother (2010) 59:419–429 425
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HPK1¡/¡ tumor-inWltrating lymphocytes (TILs) may con-
tinue to carry out their eVector function in a PGE2-rich
tumor microenvironment. The PGE2-producing Lewis lung
carcinoma cell line possesses immunosuppressive proper-
ties and is widely used as a murine model of lung cancer
with a strong T-cell involvement [23,  37,  39]. To test
whether the loss of HPK1 would result in a resistance to the
growth of 3LL, we injected 5 £ 105 3LL cells intrave-
nously into wild-type or HPK1¡/¡ mice. The presence of
tumor foci in the lungs was assessed 14 days after 3LL
injection by hematoxylin and eosin (H&E) staining. No
foci were detected in 75% of the HPK1¡/¡ mice examined,
and the remaining 25% only developed one or two tumor
foci compared to an average of 22 foci in wild-type mice
(Fig. 4a, b). Furthermore, when compared to wild-type con-
trols, the size of individual foci in the lungs of HPK1¡/¡
mice was signiWcantly smaller. Immunohistochemistry
revealed that CD3+ lymphocytic inWltrates were present in
those solitary tumor foci, whereas none was detected in the
foci of wild-type mice (Fig. 5a). Further analysis revealed
both CD4+ and CD8+ T-cell inWltrates. When PGE2 produc-
tion was blocked in wild-type mice by intraperitoneal
administration of a COX-2 inhibitor (SC-791), the number
of foci was markedly reduced compared to that from
untreated wild-type mice (Fig. 4a). Furthermore, these foci
were now inWltrated by lymphocytes (Fig. 5a), in agree-
ment with prior reports [39]. COX-2 inhibitors reduced the
number of lung foci, but not as much as the reduction in
foci seen in the HPK1¡/¡ mice. These results suggest that
besides resistance to PGE2, removing HPK1 results in an
enhanced anti-tumor response by these T cells. This inter-
pretation would be consistent with the enhanced T-cell
response seen in the HPK1¡/¡ mice, reported by Tan et al.
Taken together, our results indicate that HPK1¡/¡ mice
have a robust anti-tumor response against PGE2 producing
3LL that may consist of an enhanced T-cell response to the
tumor, as well as a resistance to PGE2 suppression.
T cell-dependent resistance of HPK1¡/¡ mice to tumor 
growth
T-cell inWltration in tumors that developed in HPK1-deW-
cient mice implicates T cells in their resistance to the
growth of Lewis lung carcinoma. To compare the anti-
tumor T-cell response of wild-type and HPK1¡/¡ mice,
splenocytes were isolated from mice that received 3LL
cells 14 days earlier, and their ability to lyse 3LL cells was
determined ex vivo by a cytotoxicity assay. When HPK1¡/¡
splenocytes were co-cultured with irradiated 3LL cells at
varying eVectors to targets (E:T) ratios, they were Wve
times more eVective in killing 3LL cells than wild-type
splenocytes (Fig. 5b). Furthermore, when supernatants from
this assay were collected and analyzed for the production of
IFN- by ELISA, signiWcantly more IFN- was detected in
the supernatants collected from HPK1¡/¡ T-cell co-cultures
versus those from wild-type T cells (Fig. 5b).
To verify the role of HPK1¡/¡ T cells in the rejection of
3LL cells, we puriWed and intravenously transferred wild-type
or HPK1¡/¡ T cells along with 3LL cells into T cell-deWcient,
RAG2¡/¡ hosts. After 14 days, there was a profound reduc-
tion in the number and size of tumor foci in the lungs of mice
that received HPK1¡/¡ T cells when compared to the number
and size of tumors from mice that received wild-type T cells
or to controls that received no T cells (Fig. 5c). These Wnd-
ings conWrm that the resistance to 3LL tumor development in
HPK1¡/¡ mice is T cell-dependent.
Discussion
The primary objective of cancer immunotherapy is to
manipulate a non-responsive immune system to eVectively
participate in tumor rejection. Our Wnding that the lack of
HPK1 resulted in an eYcient rejection of Lewis lung carci-
noma suggests that HPK1 is involved in the control of anti-
tumor immune responses. The involvement of HPK1 in the
control of anti-tumor activity is consistent with its role as a
negative regulator of TCR-induced signals [19, 38]. Similar
enhanced anti-tumor responses in mice that are deWcient in
known negative regulators have been documented. For
instance, the loss of the ubiquitin ligase activity of Cbl-b
correlates with an enhanced ability of Cbl-b¡/¡ mice to
reject transplanted, as well as spontaneously arising, tumors
[7, 21]. Administering neutralizing mAbs capable of block-
ing negative signaling pathways downstream of CTLA-4
and PD-1 also resulted in enhanced anti-tumor activity [2,
11,  14,  18,  30]. Because HPK1 and the aforementioned
negative regulators may utilize unique signaling mecha-
nisms to inhibit T-cell activation, they represent possible
targets for the development of cancer therapies.
Our initial observation that the kinase activity of HPK1
is responsive to PGE2 stimulation led us to propose that
HPK1 plays a functional role downstream of PGE2-induced
signals. Through genetic ablation of HPK1, we have gener-
ated mice whose hematopoietic cells are resistant to immu-
nosuppression mediated by PGE2 stimulation, but whose T
cells also demonstrate enhanced functions, such as prolifer-
ation, IL-2 production, and cytotoxicity. In aggregate, the
resistance to PGE2, in conjunction with the resistance to
apoptosis and the increased T-cell responsiveness to TCR-
generated signal, may contribute toward the enhanced anti-
tumor activity observed in HPK1¡/¡ mice.
Lewis lung carcinoma is a PGE2-dependent murine
model of lung cancer. The importance of PGE2 in this
model system has been demonstrated through the use of
COX-2 inhibitors and anti-PGE2 neutralizing antibodies,426 Cancer Immunol Immunother (2010) 59:419–429
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resulting in an increased anti-tumor activity and subsequent
tumor rejection by PGE2-manipulated mice [39]. The
inability of COX-2 inhibitor-treated wild-type mice to erad-
icate 3LL tumors as eYciently as HPK1¡/¡ mice does sug-
gest that an HPK1-regulated, PGE2-independent anti-tumor
mechanism(s) may also exist. Our results here demonstrate
that  HPK1¡/¡ T cells are also more resistant to PGE2-
induced apoptosis, a Wnding that is consistent with the
existing data that implicates HPK1 as a pro-apoptotic mole-
cule in TCR signaling pathways [3–5]. Not only did we
observe resistance to PGE2-induced apoptosis in HPK1¡/¡
T cells, but fewer Annexin V+ T cells were found in
CD3 + CD28 expanded HPK1¡/¡ cultures in the absence of
PGE2. These Wndings strengthened the conclusion that
HPK1 functions as a pro-apoptotic molecule downstream
of both the TCR and the EP receptors.
The concept that HPK1 function is regulated by both
PGE2 and the TCR pathways is consistent with our Wnd-
ing that TCR and PGE2 stimulation utilize distinct signal
transduction mechanisms to activate HPK1 [33]. Protein
Fig. 4 HPK1¡/¡ mice are resis-
tant to the growth of Lewis lung 
carcinoma. 3LL cells were 
injected intravenously into 
HPK1¡/¡ or wild-type mice, in 
the presence or absence of a 
COX-2 inhibitor (COX2i), and 
tumor burden in the lungs was 
assessed after 14 days. a Total 
number of lung foci and total tu-
mor area in the lungs with H&E 
staining. White and black bars 
represent HPK1¡/¡ and wild-
type conditions, respectively. 
b With H&E staining, a 20£ 
magniWcation (top panels) of a 
single lobe from the lungs of 
HPK1¡/¡ or wild-type mice, 
respectively. A single tumor 
focus of 60£ magniWcation from 
HPK1¡/¡ or wild-type lungs 
(bottom panels). P values shown 
represent the standard error of 
the mean of an experiment 
(n =6 )Cancer Immunol Immunother (2010) 59:419–429 427
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tyrosine kinase-dependent HPK1 activation via TCR
engagement also requires the interaction between HPK1
and Src homology domain-containing adapter proteins as
well as PKD activation [1]. This signaling mechanism
contrasts dramatically with the G-protein-coupled EP
receptor signaling pathway used by PGE2 stimulation to
activate HPK1. PGE2-induced HPK1 activity requires
PKA activation and does not need protein tyrosine kinase
activation or adapter protein interactions with HPK1 [33].
Taken together, these data suggest that both TCR and EP
receptors may activate HPK1 via diVerent signaling
mechanisms to achieve the same goal. Therefore, the role
of HPK1 in T-cell-mediated signaling events in response
to PGE2-producing tumors can be clearly diVerentiated
from its role as a negative regulator of TCR-mediated
events.
In conclusion, understanding the mechanism whereby
HPK1 is regulated by, and, in turn, regulates PGE2 signal
transduction pathways could provide a novel approach that
will facilitate the development of HPK1-based immuno-
therapy for cancer and perhaps inXammatory diseases that
also utilize PGE2.
Fig. 5 Enhanced anti-tumor 
T-cell response in HPK1¡/¡ 
mice. a 40£ magniWcation of 
H&E staining with superim-
posed IHC of anti-CD3, CD4, 
and CD8 staining, respectively, 
of a tumor focus from HPK1¡/¡ 
lungs. b Varying ratios of 
splenocytes, from 3LL-injected 
HPK1¡/¡ (Wlled squares) or 
wild-type (Wlled circles) mice 
were co-cultured with irradiated, 
51Cr-labeled 3LL cells. Irradi-
ated 3LL cells were co-cultured 
with splenocytes from tumor-
bearing HPK1¡/¡ (white bar) or 
wild-type (black bar) mice, and 
supernatants were collected for 
IFN- ELISA (n =3 ,  
**P < 0.01, ***P < 0.001). 
c PuriWed T cells from wild-type 
or HPK1¡/¡ mice were injected 
intravenously with 3LL cells 
into RAG2¡/¡ mice. The number 
of tumor lung foci and the tumor 
area was assessed as in Fig. 4 
(n =5 ) .   Error bars in all experi-
ments represent the standard 
error of the mean of an 
experiment428 Cancer Immunol Immunother (2010) 59:419–429
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